Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
562.39
-0.17 (-0.03%)
Dec 18, 2025, 4:00 PM EST - Market closed
Thermo Fisher Revenue
Thermo Fisher had revenue of $11.12B in the quarter ending September 27, 2025, with 4.94% growth. This brings the company's revenue in the last twelve months to $43.74B, up 3.22% year-over-year. In the year 2024, Thermo Fisher had annual revenue of $42.88B with 0.05% growth.
Revenue (ttm)
$43.74B
Revenue Growth
+3.22%
P/S Ratio
4.87
Revenue / Employee
$349,888
Employees
125,000
Market Cap
211.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 42.88B | 22.00M | 0.05% |
| Dec 31, 2023 | 42.86B | -2.06B | -4.58% |
| Dec 31, 2022 | 44.92B | 5.70B | 14.55% |
| Dec 31, 2021 | 39.21B | 6.99B | 21.71% |
| Dec 31, 2020 | 32.22B | 6.68B | 26.14% |
| Dec 31, 2019 | 25.54B | 1.18B | 4.86% |
| Dec 31, 2018 | 24.36B | 3.44B | 16.45% |
| Dec 31, 2017 | 20.92B | 2.64B | 14.47% |
| Dec 31, 2016 | 18.27B | 1.31B | 7.72% |
| Dec 31, 2015 | 16.97B | 75.40M | 0.45% |
| Dec 31, 2014 | 16.89B | 3.80B | 29.02% |
| Dec 31, 2013 | 13.09B | 580.40M | 4.64% |
| Dec 31, 2012 | 12.51B | 951.10M | 8.23% |
| Dec 31, 2011 | 11.56B | 1.17B | 11.22% |
| Dec 31, 2010 | 10.39B | 481.50M | 4.86% |
| Dec 31, 2009 | 9.91B | -586.40M | -5.59% |
| Dec 31, 2008 | 10.50B | 751.60M | 7.71% |
| Dec 31, 2007 | 9.75B | 5.95B | 157.05% |
| Dec 31, 2006 | 3.79B | 1.16B | 44.00% |
| Dec 31, 2005 | 2.63B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TMO News
- 23 hours ago - Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care - Business Wire
- 3 days ago - OlivePoint Capital Acquires 3900 Paramount Parkway in Raleigh–Durham, Expanding Its High-Conviction Office Special Situations Strategy - Business Wire
- 3 days ago - Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity - Business Wire
- 16 days ago - Thermo Fisher Scientific Deepens Investment in Asia's Biopharma Ecosystem with Expansion of Bioprocess Design Centers - Business Wire
- 17 days ago - Top 15 High-Growth Dividend Stocks For December 2025 - Seeking Alpha
- 24 days ago - Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - Business Wire
- 4 weeks ago - Thermo Fisher Scientific's Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - Business Wire
- 4 weeks ago - Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing* - Business Wire